Head to head
BioNTech vs Vertex Pharmaceuticals
Side-by-side on the measures that matter, with a plain-English read. Full detail: BNTX · VRTX
BNTX
BioNTech
93.75-1.57%
1-year price shape — -10% over the period
Quant Rating D · 28/100
vs
VRTX
Vertex Pharmaceuticals
503.51-0.42%
1-year price shape — +23% over the period
Quant Rating C · 67/100
1-year performance, rebased to 100
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (67); Vertex Pharmaceuticals has done best over the past year (+23%); Vertex Pharmaceuticals earns the most per share.
| BNTX | VRTX | |
|---|---|---|
| Snapshot | ||
| Sector | Biotechnology | Biotechnology |
| Last price | 93.75 | 503.51 |
| Change today | -1.57% | -0.42% |
| 1-year return | -10.2% | +23.2% |
| Market cap | $23.55B | $127.62B |
| 52-week range | 79.52 – 124.00 | 402.58 – 560.25 |
| Valuation | ||
| P/E (TTM) | -12.48 | 29.32 |
| P/E percentile, own 5-yr range | 41st | 74th |
| P/B | 1.18 | 6.30 |
| Dividend yield | 0.00% | 0.00% |
| Profitability & growth | ||
| EPS (TTM) | -5.26 | 15.32 |
| Net profit (TTM) | $-1.32B | $3.88B |
| Revenue (TTM) | $2.65B | $12.59B |
| Revenue growth (YoY) | -59.5% | +12.5% |
| Gross margin | 75.5% | 86.0% |
| Operating margin | -46.4% | 37.9% |
| Net margin | -63.6% | 35.0% |
| Free cash flow (TTM) | $444.70M | $3.80B |
| Ownership & sentiment | ||
| Institutional ownership | 60.7% | 97.2% |
| Insider activity (12mo) | 10 buy / 19 sell | 25 buy / 25 sell |
| Short interest (% of float) | 0.9% | 1.9% |
| Analyst consensus | 79% buy / 21% hold (14) | 88% buy / 8% hold / 4% sell (24) |
| Analyst price target | $127 (+35%) | $580 (+15%) |
| StockVane view | ||
| StockVane Quant Rating | D (28) | C (67) |
| Company | ||
| Employees | 7,807 | 6,400 |
| Founded | 2008 | 1989 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.